As the most abundant and reversible RNA modification in eukaryotic cells, m 6 A triggers a new layer of epi-transcription. M 6 A modification occurs through a methylation process modified by "writers" complexes, reversed by "erasers", and exerts its role depending on various "readers". Emerging evidence shows that there is a strong association between m 6 A and human diseases, especially cancers. Herein, we review biaspects of m 6 A in regulating cancers mediated by the m 6 A-associated proteins, which exert vital and specific roles in the development of various cancers. Generally, the --
protein (FTO) was detected to be a demethylase of m 6 A in 2011. 10 Since then, increased attention was paid to the fundamental mechanism and biological function of m 6 A significantly. 10, 11 Alpha-ketoglutarate-dependent dioxygenase homolog 5 (ALKBH5), the second RNA demethylase, was first reported in 2013. 12 Both FTO and ALKBH5
belong to the alpha-ketoglutarate-dependent dioxygenase family and catalyse m 6 A demethylation in a Fe(II)-and alpha-ketoglutaratedependent manner. 13, 14 Analogous to ALKBH5, alpha-ketoglutaratedependent dioxygenase homolog 3 (ALKBH3) has been demonstrated demethylase activity for 1-methyladenine and 3-methylcytosine. 15 Recently, Ueda et al. have reported that m 6 A was also a substrate of ALKBH3. 16 Interestingly, ALKBH3 shows a special substrate preference for RNA, targeting only m 6 A in tRNA, rather than those in mRNA or rRNA. An early study found two components of m 6 A methyltransferase in HeLa cells, termed as MT-A and MT-B. 17 Subsequently in 1997, a subunit of MT-A was identified and termed as methyltransferase-like protein 3 (METTL3). 18 However, it was until in 2013 that methyltransferase-like protein 14 (METTL14), the second component of methyltransferase, was identified. Besides, METTL3
and METTL14 belong to two separate families, but are highly homogenous. 19 Shortly following this identification, Wilms' tumour 1-associating protein (WTAP) was identified with the function of supporting the heterodimer core complex of METTL3-METTL14 to localize into nuclear speckles. 20 An additional observation in 2014 interestingly demonstrated that KIAA1429 (also known as VIRMA)
was substantially required for complete methylation. 21 After that, researchers found the depletion of VIRMA led to the largest reduction in mRNA methylation among the known writers. 22 And further studies indicate that VIRMA is engaged in recruiting METTL3-METTL14-WTAP at specific site and HAKAI is also an important component of methyltransferase. Besides, ZC3H13 plays a role in anchoring the m 6 A regulatory complex in the nucleus. 23 Additionally, Jaffrey et al. demonstrated two previously unrecognized components of the m 6 A methylation complex, namely RNA-binding motif protein 15 (RBM15) and its paralogue RBM15B, in 2016. 24 And METTL16 is also regarded as the methyltransferase that modifies U6 snRNAs and various non-coding RNAs. 25, 26 To date, the supposed core component of m 6 A methyltransferase is METTL3-METTL14-WTAP-VIRMA-HAKAI-ZC3H13.
The YTH domain family, with its RNA-binding domains, was the first identified "reader". Wang et al. indicated that YTH domain family protein 2 (YTHDF2) selectively bound to m 6 A-containing mRNA, subsequently reducing the stability of the target transcripts and affecting the degradation of the mRNA. 4 In contrast, YTH domain family protein 1 (YTHDF1) exerts its role in promoting translation efficiency. 27 In the meantime, the role of YTH domain-containing protein 1 (YTHDC1) in regulating mRNA splicing has been revealed. 28, 29 In 2017, Shi et al. showed that YTH domain family protein 3 (YTHDF3) promoted translation in synergy with YTHDF1
and affected methylated mRNA decay mediated through YTHDF2. 30 And recently, researchers have found that YTHDC2 promotes translation efficiency and decreases the mRNA abundance. 31 Apart from the YTH domain family, certain proteins in the heterogeneous nuclear ribonucleoprotein family also act as "readers". In 2015,
heterogeneous nuclear ribonucleoprotein A2-B1 (HNRNPA2B1) was first determined to bind to m 6 A-containing miRNA transcripts and promote primary miRNA processing. 32 Additionally, it was also found that the binding process between heterogeneous nuclear ribonucleo- A-specific methylated RNA immunoprecipitation with next-generation sequencing), was developed for profiling the transcriptome-wide m 6 A distribution. 6, 35 In this method, mRNA was fragmented into 100-nt-sized oligonucleotides and immunoprecipitated with an m 6 A-specific antibody.
Libraries were prepared from immunoprecipitated m 6 A-containing RNAs and then subjected to next-generation sequencing. As it relies on RNA fragmentation, its resolution is around 100-200 nt, making it hard to determine the precise locations of m 6 A in RNA and losing much stoichiometry information. 6, 36 In order to achieve a higher resolution, many methods are developed, such as PA-m A-sequencing) and SCARLET (site-specific cleavage and radioactive-labelling followed by ligation-assisted extraction and thin-layer chromatography). 37, 38 However, there still exist problems including time consumption and being unable to be subject to high-throughput applications. 38 Currently, the most effective method probably is MiCLIP (methylation individual nucleotide 44 and infertility. 12 Emerging evidence has indicated that m 6 A modification plays a significant role in certain cancers. However, the specific regulatory role of m 6 A in tumorigenesis and cancer progression needs to be fully elucidated. In this review, we will give an overall summary of m 6 A in the regulation of cancers.
| TH E D UAL ROLE OF m 6 A MOD IFICATION IN HUMAN CAN CE RS
Accumulating evidence supports the fact that the aberrant level of A-associated proteins in other cancers as follows.
| METTL3
As an important "writers", several studies have indicated the tumour suppressor role of METTL3 with up-regulating m 6 A modification.
However, the role of m 6 A is controversial in glioblastoma. Glioblastoma is an aggressive primary brain tumour in adults and has no significant improvement in survival rate so far. 46 Previous studies strongly indicated the role of m A modification was required for GSCs maintenance. 48 The underlying mechanism here is controversial with what we discussed above. The results indicated that METTL3 was upregulated in GSCs, whereas METTL3 silencing down-regulated the glioma reprogramming factors POU3F2, SOX2, SALL2 and OLIG2
and inhibited the growth of GSCs. 48 Further RNA immunoprecipitation studies identified that METTL3 methylated specific sites of SOX2-3′UTR and that the recruitment of HuR to m 6 A-modified sites was essential for SOX2 mRNA stabilization. In addition, the characteristic of radio-resistance in GSCs showed a positive relationship with the level of METTL3, in which SOX2 played a regulatory role. 
| METTL14
METTL14 performed tumour suppressor functions similar to that of METTL3 in the development of GSCs by targeting mRNA levels of ADAM19, EPHA3 and KLF4. 47 Wang et al. reported that METTL14-knockdown GSCs showed less demethylation changes as compared to METTL3-knockdown GSCs. 49 For hepatocellular carcinoma (HCC), the METTL14 expression and m 6 A level exhibited a converse tendency with the development of HCC, particularly in metastatic HCC.
The clinical data also revealed that patients with decreased METTL14 showed worse recurrence-free survival and overall sur- A level in human cells. 63 When treated with MA2, there was a dramatic inhibition of GSCs growth and self-renewal in vitro, and the sphere formation rates induced by METTL3-or METTL14-knockdown GSCs were also reversed. 47 
| ALKBH5
ALKBH5 is a nuclear 2-oxoglutarate-dependent oxygenase and is inducible by hypoxia-inducible factor 1 (HIF-1) in a large number of cells. 64 Intratumoural hypoxia is commonly found in cancers and is an essential microenvironment for cancer progression. [65] [66] [67] [68] A recent study has suggested that intratumoural hypoxia is a driving force for breast cancer progression. 69 Breast cancer stem cells (BCSCs) phenotype is specified by certain core pluripotency factors including NANOG and KLF4, which could be regulated by HIF-1. A modification of NANOG mRNA and enhanced NANOG mRNA stability. 72 In addition, ALKBH5 depletion impaired hypoxia-induced BCSCs enrichment and tumour formation. 72 Further study showed that ALKBH5 expression was required for breast cancer initiation and lung metastasis. 73 Zinc finger protein 217 (also known as ZNF217) plays a complementary role with ALKBH5 in negatively regulating m 6 A methylation. ZNF217 was identified to function as the m 6 A methyltransferase inhibitor by sequestering METTL3, consequently promoting the expression and stability of NANOG mRNA and KLF4 mRNA. 73 In addition, ZNF217 expression is also induced in an HIF-dependent manner under hypoxic conditions. Therefore, ZNF217 depletion leads to impaired hypoxiainduced consistent enrichment of BCSCs with ALKBH5 deficiency. 74 In terms of glioblastoma, inactivated ALKBH5 inhibited the proliferation and tumorigenesis of GSCs and impaired GSCs self-renewal. 75 It is widely accepted that FOXM1 plays a pivotal role in regulating GSCs proliferation and self-renewal. 76, 77 ALKBH5 was found to demethylate FOXM1 nascent transcripts and promote FOXM1 expression, whereas long non-coding RNA antisense of FOXM1 further promoted the interaction of FOXM1 nascent transcripts with ALKBH5. That makes ALKBH5-FOXM1 important for glioblastoma development.
| YTHDF2
YTHDF2 is recognized as a reader protein of m 6 A methylation and mediates the m 6 A-containing mRNA degradation. YTHDF2 was found to be up-regulated in HCC, and miR-145 was identified as an upstream regulatory factor to elevate m 6 A level by targeting YTHDF2 which was consistent with silencing of YTHDF2. 78 In addition, YTHDF2 was also found to be significantly up-regulated in prostate cancer tissues. 79 Knockdown of YTHDF2 greatly enhanced the level of m 6 A and led to the inhibition of proliferation and migration of prostate cancer cells, whereas overexpression of miR-493-3p
showed similar outcome. 79 Further experiment indicated that miR- A modification induced by overexpression of the tumour suppressor "writer"
(METTL3 and METTL14) and SAM and silencing of the oncogene "eraser" (FTO and ALKBH5) and "reader"(YTHDF2).
| m 6 A modification promotes tumour progression
A global view depicts that mutations of m 6 A regulatory genes were identified in 2.6% of AML, 2.4% of multiple myeloma and 1.0% of acute lymphoblastic leukaemia. 85 It was also observed that copy number variations (CNVs) appeared in 10.5% of AML patients, among which copy number loss of ALKBH5 was the most frequent. 
| METTL3
Regardless of its tumour suppressor role in glioblastoma, certain studies depict that METTL3 promotes cell growth, survival and invasion in several cancers. One study suggested that silencing of METTL3 in HepG2 cells was strongly associated with a noteworthy enhancement of the p53 signalling pathway. 6 In addition, it was observed that METTL3 was drastically up-regulated in HCC patients, with a positive correlation with the higher grade of HCC. 87 Tumour suppressor SOCS2 was observed to be the direct downstream target of METTL3. YTHDF2 directly recognized higher m 6 A modification of SOCS2 mRNA mediated by METTL3, which subsequently induced degradation of SOCS2. 88 Consistently, knockdown of SOCS2 drastically enhanced HCC proliferation. Collectively, up-regulation of METTL3 suppresses the expression of SOCS2 and promotes HCC development through m 6 A modification.
HBXIP is commonly identified as an oncogene and exerts a profound effect on breast cancer. 89, 90 A recent study has found that there was a strongly positive association between HBXIP and METTL3. 91 negative regulator of p-AKT which was considered to promote differentiation and inhibit self-renewal. 93 Although METTL3 was previously thought to be down-regulated in GSCs, the concept has become controversial. A recent study has supported that METTL3 was up-regulated in GSCs and that silencing of METTL3 inhibited cell growth by repressing POU3F2, SOX2, SALL2 and OLIG2. 48 Additional investigations are supposed to be initiated to further identify the underlying mechanisms of METTL3 in GSCs.
Other studies find a new paradigm of how METTL3 affects tumour development independent of m 6 A modification. 94 Lin et al.
observed that METTL3 enhanced the translation of certain oncogenes such as EGFR, TAZ, MAPKAPK2 and DNMT3A, which bears one or more m 6 A peaks near the stop codon. 94 However, surprisingly, METTL3 promoted translation independent of its methyltransferase activity or m 6 A readers, because the catalytic domain of METTL3 showed no effect in promoting translation of the above oncogenes. In addition, knockdown of YTHDF1/YTHDF2 did not influence METTL3-mediated translation. 94 These findings provide us with insight into the mechanisms of m 6 A modificationrelated proteins. 96 And it was discovered that WTAP overexpression greatly induced metastasis-associated genes such as MMP7 and MMP28 that degrade extracellular matrix components. 96 In addition, Xi et al. confirmed that WTAP was expressed at a significantly high level in gliomas and was closely correlated with the prognosis of patients with glioblastoma. 97 Interestingly, WTAP was also described as a novel oncogenic protein in AML. 98 However, the 
| METTL14
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